To Top

Search By Topic

Clinical Trial

291 Articles available
Alzheimer's Disease

First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials

PR-M12-18-NI-037
Clinical Trial

Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

PR-M12-18-NI-028
Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

PR-M12-18-NI-025
Clinical Trials

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma

PR-M12-18-NI-018
Bispecific Antibody

Regeneron’s Bispecific Antibody Candidate Shows Positive Results in Early Clinical Studies

PAO-M12-18-NI-007
Clinical Trial

First Trial Launches to Test Effectiveness of Male Contraceptive Gel

PR-M12-18-NI-001
Respiratory

Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor

PR-M11-18-NI-102
Crohn's Disease

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease

PR-M11-18-NI-092
Clinical Trial

Auritec Pharmaceuticals Completes Enrollment for its Sustained-release Depot Tacrolimus Clinical Trial

PR-M11-18-NI-078
Clinical Trial

Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

PR-M11-18-NI-084
Clinical Trials

Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica

PR-M11-18-NI-078
Clinical Trials

AIVITA Biomedical Announces Treatment of First Two Patients in Phase 2 Glioblastoma Trial

PR-M11-18-NI-073
Clinical Trials

Phase III Study Results for Peanut Allergy Therapy Are a Mixed Bag

PAO-M11-18-NI-021
Clinical Data

DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

PR-M11-18-NI-067
Clinical Study

Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at 2018 Annual Scientific Meeting

PR-M11-18-NI-063
Clinical Trial

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

PR-M11-18-NI-044
Clinical Trial Data

BD Announces Clinical Trial Data for the LUTONIX® 014 Drug-Coated Balloon Below-The-Knee IDE Trial

PR-M11-18-NI-041
Respiratory

Gala Enrolls First Subjects in an Early Feasibility Study of RheOx™ for Chronic Bronchitis in the United States

PR-M11-18-NI-023
Clinical Trials

Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH

PR-M11-18-NI-022
Cholesterol

Third PCSK9 Inhibitor for Lowering Cholesterol Moves into Phase III Trials

PAO-M11-18-NI-005
Osteoarthritis

High-Valued Start-Up Announces Positive Results for Osteoarthritis Drug

PAO-M11-18-NI-003
Macular Degeneration

More Positive Results for Novartis Eye Drug Brolucizumab

PAO-M11-18-NI-002
Crohn's

Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

PR-M10-18-NI-106
Diabetes

ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes

PR-M10-18-NI-105
Clinical Trials

RegeneRx Partner Updates on Clinical Trials

PR-M10-18-NI-102
PR-M10-18-NI-081

BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial

Investment
Clinical Trials

Reistone Biopharma, a New Chinese Biotech Company Ready to Initiate its Ulcerative Colitis Phase II Clinical Trial Globally

PR-M10-18-NI-076
Clinical Trials

Ward MM and Endocanna Health Announce Partnership Supporting Medicinal Cannabis Clinical Trials

PR-M10-18-NI-074
Antibiotics

PolyPid Begins Phase 2 Study to Assess Safety and Efficacy of D-PLEX100 in Prevention of Abdominal Surgical Site Infections

PR-M10-18-NI-070
ADHD

Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial

PR-M10-18-NI-066
Stem Cells

Cellect Announces Positive Clinical Results

PR-M10-18-NI-065
Clinical Trials

New Diabetes Drug Shows Promise in Phase 2 Study

PAO-M10-18-NI-012
Oncology

Targovax Reports Encouraging Disease-free Survival (DFS) Data From Tg01 Trial in Resected Pancreatic Cancer

PR-M10-18-NI-055
Clinical Trials

OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA®

PR-M10-18-NI-053
Phase 3

Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301

PR-M10-18-NI-054
Clinical Trials

New Clinical Trial Will Evaluate Biomarkers as Predictors of Treatment Response in IBD

PAO-M10-18-NI-009
Clinical Study

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

PR-M10-18-NI-024
Vaccine

Promising Phase 2b Results for New GSK Tuberculosis Vaccine

PAO-M10-18-NI-002
FDA

FDA Removes Partial Clinical Hold on Tazemetostat Clinical Trials

PAO-M09-18-NI-024
Clinical Trial

Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon

PR-M09-18-NI-066
Study Results

Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

PR-M09-18-NI-051
Clinical Data

Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting

PR-M09-18-NI-043
Study Results

Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1

PR-M09-18-NI-045
Phase 2

Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review

PR-M09-18-NI-041
Research

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

PR-M09-18-NI-040
Oncology

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

PR-M09-18-NI-038
Clinical Trial

First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)

PR-M09-18-NI-012
Phase I

Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

PR-M09-18-NI-007
Clinical Trials

GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial

PR-M09-18-NI-006
Clinical Trial

Enrollment Passes Halfway Milestone in Clinical Trial Evaluating the Effect of an Exclusive Human Milk Diet

PR-M08-18-NI-122
Study Results

VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

PR-M08-18-NI-119
Clinical Trial

I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes

PR-M08-18-NI-116
FDA Guidance

FDA Published Draft Guidance on Use of Placebo Control Groups

PAO-M08-18-NI-029
Clinical Data

Novartis Reports Promising Results for its New Alpha Specific PI3K Inhibitor BYL719

PAO-M08-18-NI-028
Clinical Trial

Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A

PR-M08-18-NI-113
Clinical Trial

Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial

PR-M08-18-NI-085
Clinical Trial

First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

PR-M08-18-NI-095
Supply Chain

Marken Offers First Hybrid Service from Brazil to USA

PR-M08-18-NI-124
Clinical Trials

60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO

PR-M08-18-NI-123
Clinical Trials

Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib

PR-M08-18-NI-035
Opening

DPS Group and TRIA Celebrate Opening of State-of-the-Art cGMP mRNA Clinical Manufacturing Facility for Moderna Therapeutics

PR-M07-18-NI-077
Clinical Trials

Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials

PR-M07-18-NI-067
Phase 3

PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study

PR-M07-18-NI-062
FDA Approval

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

PR-M07-18-NI-047
Clinical Trials

CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China

PR-M07-18-NI-042
Clinical Research

Eating Well Might Improve Cancer Treatments

PAO-M07-18-NI-006
Drug Development

SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

PR-M07-18-NI-039
Clinical Study

BioArctic Receives Regulatory Approval in Finland for a Clinical Study in Patients With Complete Spinal Cord Injury

PR-M07-18-NI-033
Biosimilars

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab

PR-M06-18-NI-100
Clinical Trials

Javara Launches Next Generation Integrated Clinical Trials Platform

PR-M06-18-NI-088
Clinical Trials

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

PR-M06-18-NI-091
Press Releases

Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies

Clinical Data

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In

PR-M06-18-NI-086
Clinical Trials

Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin

PR-M06-18-NI-083
Clinical Trials

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

PR-M06-18-NI-072
Clinical Data

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

PR-M06-18-NI-062
Clinical Trials

BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

PR-M06-18-NI-059
Trial Results

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

PR-M06-18-NI-041
Clinical Data

More Positive Phase 3 Results for Roche’s Tecentriq

PAO-M05-18-NI-024
Clinical Trials

Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile

PAP-Q2-18-CL-002
Clinical Trials

Splash Pharmaceuticals Announces Dose Escalation in Phase I Clinical Trial in Platinum-resistant Ovarian Cancer Patients

PR-M05-18-NI-109
Clinical Trial

Sanofi: Accelerating Future Breakthroughs Through Clinical Trials -- Part 2 of 3

PR-M05-18-NI-080
Clinical Trial

Research Ready™ Program Expands and Diversifies Clinical Trial Patient Populations

PR-M05-18-NI-065
Oncology

Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review

PAO-M05-18-NI-009
Clinical Trials

Merck Provides Update on KEYNOTE-407 Trial

PR-M05-18-NI-026
Clinical Data

Study Shows AST-005 is Safe and Tolerable in Patients at Higher Doses than Previously Studied

PAO-M05-18-NI-003
Clinical Data

DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease

PR-M04-18-NI-004
Vaccine

Vaccibody moving forward with Cancer Neoantigen Vaccine Trial

PR-M04-18-NI-79
Oncology

New Breast Cancer Drug Accepted for Review by EMA

PAO-M04-18-NI-010
Clinical Trials

Eli Lilly Gets Good News for Cyramza

PAO-M04-18-NI-009
Clinical Trials

First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer

PR-M04-18-NI-33
Clinical Trials

SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial

PR-M04-18-NI-020
Results

Positive Results for Pfizer Drug Tafamidis

PAO-M04-18-NI-001
Clinical Trials

Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

PR-M04-18-NI-005
Clinical Trials

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine

PR-M04-18-NI-001
Clinical Data

Clinical Study Data for New MS Drug Looks Promising

PR-M03-18-NI-101
Clinical Trials

BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients

PR-M03-18-NI-108
Clinical Data

New Study finds younger aged children with symptoms of ADHD have reduced brain size

PR-M03-18-NI-101
Clinical Trials

Clinical Trial Access to Expand Following Receipt of Additional Funding    

PAO-M03-18-NI-026
Clinical Data

Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

PR-M03-18-NI-095
Clinical Trials

Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX®  (varenicline) in Adolescent Smokers

PR-M03-18-NI-093
Clinical Trials

AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T)

PR-M03-18-NI-088
Clinical Trial Data

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis

PR-M03-18-NI-086
Clinical Trials

Late-breaking Clinical Trial Data Further Demonstrate Safety and Effectiveness of the RHYTHMIA™ Mapping System

PR-M03-18-NI-083
Acquisition

Worldwide Clinical Trials Acquires Continuum Clinical’s Late Stage Research Practice

PR-M03-18-NI-065
Research

PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea

PR-M03-18-NI-056
Clinical Trials

AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

PR-M03-18-NI-057